The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | The role of ctDNA in lung cancer screening
Frank McCaughan, MRCP(UK), MD, PhD, FRCP, University of Cambridge, Cambridge, UK, provides an overview of the functionality of circulating tumor DNA (ctDNA) in diagnosing lung cancer. Using ctDNA has evolved from detecting certain mutations to whole genome sequencing, and plays an important part in early detection, as well as in a perioperative setting; detecting stage III/VI tumors with ctDNA at the time of surgery has demonstrated to have a prognostic impact. Dr McCaughan additionally discusses the potential impact of minimal residual disease (MRD) in diagnosing lung cancer. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
